Glecirasib Shows Promising Efficacy in KRAS-Mutated NSCLC
(MedPage Today) -- Glecirasib, a highly selective covalent oral inhibitor of KRAS G12C, demonstrated promising efficacy in patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to a phase II trial from... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 1, 2024 Category: Hematology Source Type: news
WHO Africa Advances African Science by Promoting Peer-Reviewed Rese
This article is brought to you by IPS Noram in collaboration with INPS Japan and Soka Gakkai International in consultative status with ECOSOC.
IPS UN Bureau Report
Follow @IPSNewsUNBureau
!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+'://platform.twitter.com/widgets.js';fjs.parentNode.insertBefore(js,fjs);}}(document, 'script', 'twitter-wjs');
When the Man Who Built the Bombs Met the Man Who Dropped the Bombs…
Ahead of UN Summit of the Future, Mobilizing Youth for Change
UN Environmenta...
Source: IPS Inter Press Service - Health - April 29, 2024 Category: International Medicine & Public Health Authors: Maina Waruru Tags: Africa Development & Aid Editors' Choice Featured Headlines Health Humanitarian Emergencies Population Poverty & SDGs Sustainable Development Goals TerraViva United Nations IPS UN Bureau IPS UN Bureau Report SDGs for All World Source Type: news
WHO Africa Advances African Science by Promoting Peer-Reviewed Research
This article is brought to you by IPS Noram in collaboration with INPS Japan and Soka Gakkai International in consultative status with ECOSOC.
IPS UN Bureau Report
Follow @IPSNewsUNBureau
!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+'://platform.twitter.com/widgets.js';fjs.parentNode.insertBefore(js,fjs);}}(document, 'script', 'twitter-wjs');
When the Man Who Built the Bombs Met the Man Who Dropped the Bombs…
Ahead of UN Summit of the Future, Mobilizing Youth for Change
UN Environmenta...
Source: IPS Inter Press Service - Health - April 29, 2024 Category: International Medicine & Public Health Authors: Maina Waruru Tags: Africa Development & Aid Editors' Choice Featured Headlines Health Humanitarian Emergencies Population Poverty & SDGs Sustainable Development Goals TerraViva United Nations IPS UN Bureau IPS UN Bureau Report SDGs for All World Source Type: news
CHMP recommends EU approval of Roche ’s Alecensa as the first adjuvant treatment for resected ALK-positive early-stage lung cancer
If approved, Alecensa will be the first and only ALK inhibitor approved for people with resected ALK-positive early-stage non-small cell lung cancer (NSCLC)The positive recommendation is based on results from the Phase III ALINA study where Alecensa showed an unprecedented 76% reduction in the risk of disease recurrence or death, compared to adjuvant chemotherapy1With about half of people living with early-stage NSCLC experiencing disease recurrence or death following surgery, Alecensa could minimise the risk by treating NSCLC before it has spread2Basel, 26 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today th...
Source: Roche Investor Update - April 26, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with abouthalf of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2TheNational Comprehensive Cancer Network ® (NCCN®)Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selectionBasel, 19 April 2024 - Roche (SIX: RO,...
Source: Roche Investor Update - April 19, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with abouthalf of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2TheNational Comprehensive Cancer Network ® (NCCN®)Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selectionBasel, 19 April 2024 - Roche (SIX: RO,...
Source: Roche Media News - April 19, 2024 Category: Pharmaceuticals Source Type: news
Urine Test for Detecting Head and Neck Cancer
At-home test can detect tumor DNA fragments in urine samples, providing a non-invasive alternative to traditional blood-based biomarker tests (Source: Disabled World)
Source: Disabled World - April 16, 2024 Category: Disability Tags: Head, Neck, and Oral Cancer Source Type: news
How a lollipop can help to spot the early signs of mouth cancer
When the fruit-flavoured sweet, which is being developed by scientists at Birmingham University, is sucked for just a few minutes, the proteins - released by mouth cancer cells - become 'stuck' (Source: the Mail online | Health)
Source: the Mail online | Health - April 15, 2024 Category: Consumer Health News Source Type: news
April is Oral Cancer Awareness Month: Self-exams, early detection can save lives
The American Association of Oral and Maxillofacial Surgeons (AAOMS) is reminding the public during Oral Cancer Awareness Month of the importance of performing monthly self-exams. ROSEMONT, Ill., April 11, 2024 /PRNewswire-PRWeb/ -- Early detection of oral cancer offers a greater chance of... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 11, 2024 Category: Pharmaceuticals Source Type: news
Why a New Study Dubbed India the ‘Cancer Capital of the World’
A new study has unveiled an alarming picture of declining overall health in India. The report, released by the Indian multinational healthcare group, Apollo Hospitals, found that skyrocketing cases of cancer and other non-communicable diseases across the country have now made it “the cancer capital of the world.”
[time-brightcove not-tgx=”true”]
Despite reporting more than a million new cases every year, India’s cancer rate has not yet surpassed countries like Denmark, Ireland, and Belgium, which record some of the highest cancer rates in the world. It is also currently lower than the U.S....
Source: TIME: Health - April 10, 2024 Category: Consumer Health News Authors: Astha Rajvanshi Tags: Uncategorized India Source Type: news
Experts warn morning breath could be a red flag sign of killer cancer
If improving your oral hygiene doesn't get rid of bad breath it is time to see a health professional, an expert has warned. (Source: Daily Express - Health)
Source: Daily Express - Health - March 25, 2024 Category: Consumer Health News Source Type: news
How to Manage Anxiety and Depression When You Have Kidney Cancer
When Katie Coleman was diagnosed at age 29 with a softball-sized tumor on her right kidney and a host of smaller growths in her liver, she was stunned. That astonishment quickly gave way to feelings of hopelessness. “I felt like my entire world was being pulled out from under me,” Coleman, now 32, says. “I went into a very dark spiral.”
Though her surgeon removed all the tumors, it wasn’t clear what her long- or even short- term prognosis was. What she found on the internet just freaked her out more. “One night I spiraled so deep I didn’t know whether life was worth living anymo...
Source: TIME: Health - March 22, 2024 Category: Consumer Health News Authors: Linda Carroll Tags: Uncategorized freelance healthscienceclimate Source Type: news
Broader Cancer Risk With CAR-T? AI for Physician Burnout; 'Lollipops' ID Oral Cancer
(MedPage Today) -- T-cell malignancies represent a small fraction of secondary cancers in patients treated with CAR T-cell therapy. (American Society of Hematology)
In an update to a clinical guideline, the American Society of Clinical Oncology... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 22, 2024 Category: Hematology Source Type: news
A Bacteria in the Mouth Might Speed Colon Cancers
THURSDAY, March 21, 2024 -- A germ commonly found in the human mouth can travel to colon tumors and appears to speed their growth, new research shows.
The finding might lead to new insights into fighting colon cancer, which kills more than 52,000... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 21, 2024 Category: General Medicine Source Type: news
Bacteria commonly found in the body contribute to stomach cancer
A new study has discovered that a type of bacteria commonly found in the body, which usually does not pose problems for healthy people, plays a significant role in causing stomach cancer, the fifth most common cancer in the world.
Streptococcus anginosus bacteria exist alongside other germs in the mouth, throat, intestines and vagina. Occasionally, they may cause mild infections like sore throats and skin infections. (Source: World Pharma News)
Source: World Pharma News - March 18, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
